24.46

0.41% -0.10

After Hours: 24.75 0.29 +1.19%

Quidelortho Corporation (QDEL)

Overview News Price History Option Chain Financials Discussions Forecast

Quidelortho Corporation stock is traded at $24.46, with a volume of 1.45M. It is down -0.41% in the last 24 hours and down -31.92% over the past month. QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Previous Close:

$24.56

Open:

$24.91

24h Volume:

1.45M

Relative Volume:

1.45

Market Cap:

$1.79B

Revenue:

$2.82B

Net Income/Loss:

$-1.87B

P/E Ratio:

-0.8767

EPS:

-27.9

Net Cash Flow:

$-96.80M

1W Performance:

-7.91%

1M Performance:

-31.92%

6M Performance:

-38.31%

1Y Performance:

-37.41%

1-Day Range:

$24.38

$25.39

1-Week Range:

$23.77

$26.50

52-Week Range:

$23.77

$49.45

Quidelortho Corporation Stock (QDEL) Company Profile

Name

Quidelortho Corporation

Sector

Healthcare (1153)

Industry

Medical Devices (154)

Phone

(858) 552-1100

Address

9975 SUMMERS RIDGE ROAD, SAN DIEGO, CA

Employee

6,600

Twitter

@QuidelDX

Next Earnings Date

2024-11-07

Latest SEC Filings

QDEL's Discussions on Twitter

Compare QDEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
QDEL Quidelortho Corporation	24.46	1.79B	2.82B	-1.87B	-96.80M	-27.90
ABT Abbott Laboratories	131.73	218.91B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	95.05	139.37B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	348.12	134.90B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	83.37	106.90B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	70.60	41.45B	5.72B	4.17B	259.90M	6.97

Quidelortho Corporation Stock (QDEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-11-24	Upgrade	Citigroup	Neutral → Buy
Dec-10-24	Initiated	Jefferies	Hold
Sep-19-24	Resumed	UBS	Neutral
Sep-05-24	Upgrade	Craig Hallum	Hold → Buy
Mar-04-24	Downgrade	UBS	Neutral → Sell
Feb-14-24	Downgrade	JP Morgan	Neutral → Underweight
Dec-11-23	Downgrade	Citigroup	Buy → Neutral
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Oct-14-22	Upgrade	UBS	Sell → Neutral
Sep-19-22	Initiated	Citigroup	Neutral
Jul-20-22	Initiated	UBS	Sell
Jun-17-22	Resumed	JP Morgan	Neutral
Feb-22-22	Upgrade	Raymond James	Outperform → Strong Buy
Jan-22-21	Upgrade	Raymond James	Mkt Perform → Outperform
May-12-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-26-20	Downgrade	Barclays	Overweight → Equal Weight
Oct-23-18	Resumed	Raymond James	Strong Buy
Mar-08-18	Upgrade	Raymond James	Outperform → Strong Buy
Jan-22-18	Reiterated	Barclays	Overweight
Jan-04-18	Upgrade	CL King	Neutral → Buy
Sep-19-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-17	Upgrade	Canaccord Genuity	Hold → Buy
Jul-18-17	Upgrade	William Blair	Mkt Perform → Outperform
Apr-25-17	Reiterated	Canaccord Genuity	Hold
Feb-17-17	Initiated	CL King	Neutral
Dec-16-16	Downgrade	Piper Jaffray	Overweight → Neutral
Jun-13-16	Upgrade	Raymond James	Mkt Perform → Outperform
Feb-18-16	Reiterated	Barclays	Overweight
Feb-09-16	Downgrade	Canaccord Genuity	Buy → Hold
Jan-08-16	Reiterated	Canaccord Genuity	Buy
Dec-14-15	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-02-15	Initiated	Barclays	Overweight
Jul-31-13	Reiterated	Canaccord Genuity	Buy
Mar-03-11	Downgrade	Wedbush	Outperform → Neutral

View All

Quidelortho Corporation Stock (QDEL) Latest News

Apr 22, 2025

QuidelOrtho Co. (NASDAQ:QDEL) Position Reduced by Bank of Montreal Can - Defense World

Apr 22, 2025

QuidelOrtho (NASDAQ:QDEL) Reaches New 52-Week Low on Analyst Downgrade - Defense World

Apr 22, 2025

Apr 21, 2025